From 6 referral hospitals that share the same electronic medical records system, the medical records of patients diagnosed with type 2 diabetes mellitus (T2DM) by internists who underwent vitrectomy for DR and were followed up with for at least 1 year between January 2009 and July 2020 were obtained. The diagnosis of type T2DM was made based on a fasting plasma glucose level of at least 126 mg/dL or 2-hour post-glucose level of at least 200 mg/dL after a 75-g oral glucose tolerance test.
14 Patients who underwent vitrectomy for PDR were identified by operation title and diagnosis for operation. Included diagnoses were vitreous hemorrhage, proliferative membrane, and/or tractional retinal detachment.
Clinical data—including age at operation; duration of T2DM treatment in the referral hospital; sex, height, and weight; smoking status; systolic and diastolic blood pressure values; and the use of insulin, aspirin, and clopidogrel—were collected. Body mass index (BMI) and mean arterial pressure (MAP) were calculated. Co-existing hypertension, chronic kidney disease (CKD), cardiovascular disease, and cerebrovascular disease were assessed. From laboratory tests, serum levels of glucose at random, glycated hemoglobin (HbA1c), alanine aminotransferase (AST), aspartate aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine within 1 month prior to surgery were collected. From ophthalmologic records, visual acuity (VA) values at baseline and 1, 3, 6, and 12 months after surgery; intra-operative findings (e.g. vitreous hemorrhage, tractional membrane, macular edema, and neovascular glaucoma), use of pre-, intra-, or postoperative bevacizumab; and concomitant procedures (e.g. phacoemulsification, scleral encircling, and silicone oil tamponade) were collected.